pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·1d ago·1 min read
save

Start Center for Cancer Research opens first early-phase clinical trial site in Italy

Start Center for Cancer Research has expanded into Italy, partnering with Istituti Fisioterapici Ospitalieri to open its first early-phase cancer clinical trial site in the country.

Nov 10, 2026·read at Fierce Biotech ↗

CRO Start Center for Cancer Research opens first early-phase clinical trial site in Italy By Marissa Russo Nov 10, 2026 12:41pm clinical trials Italy Cancer The Start Center for Cancer Research has opened its first cancer clinical trial site in Italy.Start teamed up with Italian public research hospital organization Istituti Fisioterapici Ospitalieri (IFO) to open an early-phase clinical trial site at the Regina Elena National Cancer Institute. The partnership aims to expand access to investigational cancer therapies for eligible patients in Rome, the Lazio region and across Italy.According to a 2025 report, Italy records approximately 390,000 new cancer diagnoses a year. Despite the high incidence, Italy has fewer clinical trials relative to its population than several major Western European markets, according to Start's Nov.

3 news release. Through the partnership, Start will bring its expertise in early-phase oncology research and its global portfolio of industry-sponsored clinical trials to the institute.IFO operates the Regina Elena National Cancer Institute, which combines patient care and biomedical research and treats patients at every stage of cancer. Regina Elena provides care for patients with major solid tumors, rare cancers and hematologic malignancies.“Italy has a substantial cancer burden and world-class institutions, yet clinical trial activity relative to population remains lower than in several other major European markets,” Nick Slack, CEO of Start, said in the release.“By partnering with IFO and the Regina Elena National Cancer Institute, an established leader in Italian cancer care and research, we can bring early-phase oncology research closer to patients across Italy and advance our mission of providing Hope Through Access.” clinical trials Italy Cancer CRO

source

Reporting by Fierce Biotech.

read at Fierce Biotech ↗
264 words · retrieved 5m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 9h agoValo and Montai become one as the Flagship AI-based biotechs tie the knotFierce Biotech
  • 10h agoBioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’Fierce Biotech
  • 13h agoCapricor, NextCure shed light on recent layoffs as they gear up for approval decision, mergerFierce Biotech
  • 13h agoAmgen builds Sjögren’s case with detailed phase 3 data ahead of Novartis showdownFierce Biotech
  • 17h agoAbbott nabs FDA approval, CE Mark for implantable cardioverter-defibrillator leadFierce Biotech